Abuse Deterrent Access Act of 2018

Bill: 115-hr-5582
Sponsor: full_name: Rep. Carter, Earl L. "Buddy" [R-GA-1]
Introduced: 2018-04-23
Policy area: Health
Subjects: Congressional oversight

Drug therapy

Drug trafficking and controlled substances

Drug, alcohol, tobacco use

Government studies and investigations

Health care costs and insurance

Health care coverage and access

Health promotion and preventive care

Medicare

Prescription drugs
Latest action: action_date: 2018-06-13
text: Received in the Senate and Read twice and referred to the Committee on Finance.

Summaries:
action_date: 2018-04-23
action_desc: Introduced in House
text: <p><b>Abuse Deterrent Access Act of 2018</b><br /></p> <p>This bill requires the Centers for Medicare &amp; Medicaid Services to report to Congress on the adequacy of access to abuse-deterrent opioid formulations for individuals with chronic pain enrolled in&nbsp;a&nbsp;prescription drug plan under Medicare or Medicare Advantage (MA). The report&nbsp;must account for&nbsp;any barriers preventing enrollees from accessing such formulations under Medicare or MA. </p>

action_date: 2018-06-08
action_desc: Reported to House with amendment(s)
text: <p><b>Abuse Deterrent Access Act of 2018</b><br /> </p> <p>This bill requires the Centers for Medicare &amp; Medicaid Services to report to Congress on the adequacy of access to abuse-deterrent opioid formulations for individuals with chronic pain enrolled in&nbsp;a&nbsp;prescription drug plan under Medicare or Medicare Advantage (MA). The report&nbsp;must account for&nbsp;any barriers preventing enrollees from accessing such formulations under Medicare or MA. </p>

action_date: 2018-06-12
action_desc: Passed House amended
text: <p><b>Abuse Deterrent Access Act of 2018</b><br /> </p> <p>(Sec. 2) This bill requires the Centers for Medicare &amp; Medicaid Services to report to Congress on the adequacy of access to abuse-deterrent opioid formulations for individuals with chronic pain enrolled in&nbsp;a&nbsp;prescription drug plan under Medicare or Medicare Advantage (MA). The report&nbsp;must account for&nbsp;any barriers preventing enrollees from accessing such formulations under Medicare or MA. </p>

tv_txt: I 115th CONGRESS 2d Session H. R. 5582 IN THE HOUSE OF REPRESENTATIVES April 23, 2018 Mr. Carter of Georgia (for himself, Mr. Loebsack , and Mr. Reed ) introduced the following bill; which was referred to the Committee on Energy and Commerce , and in addition to the Committee on Ways and Means , for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned A BILL To direct the Secretary of Health and Human Services to conduct a study and submit a report on barriers to accessing abuse-deterrent opioid formulations for individuals enrolled in a plan under part C or D of the Medicare program.

1. Short title This Act may be cited at the Abuse Deterrent Access Act of 2018 . 2. Study on abuse-deterrent opioid formulations access barriers under Medicare (a) In general Not later than 180 days after the date of the enactment of this Act, the Secretary of Health and Human Services shall conduct a study and submit to Congress a report on the adequacy of access to abuse-deterrent opioid formulations for individuals with chronic pain enrolled in an MA–PD plan under part C of title XVIII of the Social Security Act or a prescription drug plan under part D of such title of such Act, taking into account any barriers preventing such individuals from accessing such formulations under such MA–PD or part D plans, such as cost-sharing tiers, fail-first requirements, and prior authorization requirements. (b) Definition of abuse-deterrent opioid formulation In this section, the term abuse-deterrent opioid formulation means an opioid with certain abuse-deterrent properties, such as physical or chemical barriers, agonist or antagonist combinations, aversion properties, delivery system mechanisms, or other features designed to prevent abuse of such opioid.

tv_txt: I 115th CONGRESS 2d Session H. R. 5582 IN THE HOUSE OF REPRESENTATIVES AN ACT To direct the Secretary of Health and Human Services to conduct a study and submit a report on barriers to accessing abuse-deterrent opioid formulations for individuals enrolled in a plan under part C or D of the Medicare program.

1. Short title This Act may be cited at the Abuse Deterrent Access Act of 2018 . 2. Study on abuse-deterrent opioid formulations access barriers under Medicare (a) In general Not later than on1e year after the date of the enactment of this Act, the Secretary of Health and Human Services shall conduct a study and submit to Congress a report on the adequacy of access to abuse-deterrent opioid formulations for individuals with chronic pain enrolled in an MA–PD plan under part C of title XVIII of the Social Security Act or a prescription drug plan under part D of such title of such Act, taking into account any barriers preventing such individuals from accessing such formulations under such MA–PD or part D plans, such as cost-sharing tiers, fail-first requirements, the price of such formulations, and prior authorization requirements. (b) Definition of abuse-Deterrent opioid formulation In this section, the term abuse-deterrent opioid formulation means an opioid that is a prodrug or that has certain abuse-deterrent properties, such as physical or chemical barriers, agonist or antagonist combinations, aversion properties, delivery system mechanisms, or other features designed to prevent abuse of such opioid.

Passed the House of Representatives June 12, 2018. Karen L. Haas, Clerk.

tv_txt: IIB 115th CONGRESS 2d Session H. R. 5582 IN THE SENATE OF THE UNITED STATES June 13, 2018 Received; read twice and referred to the Committee on Finance AN ACT To direct the Secretary of Health and Human Services to conduct a study and submit a report on barriers to accessing abuse-deterrent opioid formulations for individuals enrolled in a plan under part C or D of the Medicare program.

1. Short title This Act may be cited at the Abuse Deterrent Access Act of 2018 . 2. Study on abuse-deterrent opioid formulations access barriers under Medicare (a) In general Not later than on1e year after the date of the enactment of this Act, the Secretary of Health and Human Services shall conduct a study and submit to Congress a report on the adequacy of access to abuse-deterrent opioid formulations for individuals with chronic pain enrolled in an MA–PD plan under part C of title XVIII of the Social Security Act or a prescription drug plan under part D of such title of such Act, taking into account any barriers preventing such individuals from accessing such formulations under such MA–PD or part D plans, such as cost-sharing tiers, fail-first requirements, the price of such formulations, and prior authorization requirements. (b) Definition of abuse-Deterrent opioid formulation In this section, the term abuse-deterrent opioid formulation means an opioid that is a prodrug or that has certain abuse-deterrent properties, such as physical or chemical barriers, agonist or antagonist combinations, aversion properties, delivery system mechanisms, or other features designed to prevent abuse of such opioid.

Passed the House of Representatives June 12, 2018. Karen L. Haas, Clerk

tv_txt: IB Union Calendar No. 556 115th CONGRESS 2d Session H. R. 5582 [Report No. 115–721, Part I] IN THE HOUSE OF REPRESENTATIVES April 23, 2018 Mr. Carter of Georgia (for himself, Mr. Loebsack , and Mr. Reed ) introduced the following bill; which was referred to the Committee on Energy and Commerce , and in addition to the Committee on Ways and Means , for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned June 8, 2018 Additional sponsors: Mr. Michael F. Doyle of Pennsylvania , Mrs. Blackburn , Mr. Walden , and Mr. McHenry June 8, 2018 Reported from the Committee on Energy and Commerce with an amendment Strike out all after the enacting clause and insert the part printed in italic June 8, 2018 The Committee on Ways and Means discharged; committed to the Committee of the Whole House on the State of the Union and ordered to be printed For text of introduced bill, see copy of bill as introduced on April 23, 2018 A BILL To direct the Secretary of Health and Human Services to conduct a study and submit a report on barriers to accessing abuse-deterrent opioid formulations for individuals enrolled in a plan under part C or D of the Medicare program.

1. Short title This Act may be cited at the Abuse Deterrent Access Act of 2018 . 2. Study on abuse-deterrent opioid formulations access barriers under Medicare (a) In general Not later than one year after the date of the enactment of this Act, the Secretary of Health and Human Services shall conduct a study and submit to Congress a report on the adequacy of access to abuse-deterrent opioid formulations for individuals with chronic pain enrolled in an MA–PD plan under part C of title XVIII of the Social Security Act or a prescription drug plan under part D of such title of such Act, taking into account any barriers preventing such individuals from accessing such formulations under such MA–PD or part D plans, such as cost-sharing tiers, fail-first requirements, the price of such formulations, and prior authorization requirements. (b) Definition of abuse-deterrent opioid formulation In this section, the term abuse-deterrent opioid formulation means an opioid that is a prodrug or that has certain abuse-deterrent properties, such as physical or chemical barriers, agonist or antagonist combinations, aversion properties, delivery system mechanisms, or other features designed to prevent abuse of such opioid.

June 8, 2018 Reported from the Committee on Energy and Commerce with an amendment June 8, 2018 The Committee on Ways and Means discharged; committed to the Committee of the Whole House on the State of the Union and ordered to be printed